Literature DB >> 10743948

5-Arylamino-2-methyl-4,7-dioxobenzothiazoles as inhibitors of cyclin-dependent kinase 4 and cytotoxic agents.

C K Ryu1, H Y Kang, S K Lee, K A Nam, C Y Hong, W G Ko, B H Lee.   

Abstract

5-Arylamino-2-methyl-4,7-dioxobenzothiazoles were synthesized as inhibitors of cyclin-dependent kinase 4 (CDK4) and cytotoxic agents. Most of the 4,7-dioxobenzothiazoles exhibited selective inhibitory activities for the CDK4 and cytotoxic potential against human cancer cell lines.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10743948     DOI： 10.1016/s0960-894x(00)00014-7

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN： 0960-894X            Impact factor:   2.823


  9 in total

Review 1.  The CDK inhibitors in cancer research and therapy.

Authors:  Jonas Cicenas; Mindaugas Valius
Journal:  J Cancer Res Clin Oncol       Date:  2011-08-30       Impact factor: 4.553

2.  Cyclin-dependent kinase-mediated phosphorylation plays a critical role in the oncogenic functions of PELP1.

Authors:  Binoj C Nair; Sujit S Nair; Dimple Chakravarty; Rambabu Challa; Bramanandam Manavathi; P Renee Yew; Rakesh Kumar; Rajeshwar Rao Tekmal; Ratna K Vadlamudi
Journal:  Cancer Res       Date:  2010-08-31       Impact factor: 12.701

3.  Highly Active Small Aminated Quinolinequinones against Drug-Resistant Staphylococcus aureus and Candida albicans.

Authors:  Hatice Yıldırım; Nilüfer Bayrak; Mahmut Yıldız; Fatıma Nur Yılmaz; Emel Mataracı-Kara; Deepak Shilkar; Venkatesan Jayaprakash; Amaç Fatih TuYuN
Journal:  Molecules       Date:  2022-05-03       Impact factor: 4.927

4.  A high through-put screen for small molecules modulating MCM2 phosphorylation identifies Ryuvidine as an inducer of the DNA damage response.

Authors:  Jennifer FitzGerald; Laura S Murillo; Gemma O'Brien; Enda O'Connell; Aisling O'Connor; Kevin Wu; Guan-Nan Wang; Michael D Rainey; Alessandro Natoni; Sandra Healy; Michael O'Dwyer; Corrado Santocanale
Journal:  PLoS One       Date:  2014-06-05       Impact factor: 3.240

5.  Small-molecule inhibitors of SETD8 with cellular activity.

Authors:  Gil Blum; Glorymar Ibáñez; Xiangjun Rao; David Shum; Constantin Radu; Hakim Djaballah; Judd C Rice; Minkui Luo
Journal:  ACS Chem Biol       Date:  2014-09-03       Impact factor: 5.100

Review 6.  Highlights of the Latest Advances in Research on CDK Inhibitors.

Authors:  Jonas Cicenas; Karthik Kalyan; Aleksandras Sorokinas; Asta Jatulyte; Deividas Valiunas; Algirdas Kaupinis; Mindaugas Valius
Journal:  Cancers (Basel)       Date:  2014-10-27       Impact factor: 6.639

7.  Identification of ryuvidine as a KDM5A inhibitor.

Authors:  Eishin Mitsui; Shogo Yoshida; Yui Shinoda; Yasumasa Matsumori; Hiroshi Tsujii; Mie Tsuchida; Shuichi Wada; Makoto Hasegawa; Akihiro Ito; Koshiki Mino; Tetsuo Onuki; Minoru Yoshida; Ryuzo Sasaki; Tamio Mizukami
Journal:  Sci Rep       Date:  2019-07-09       Impact factor: 4.379

8.  Green Synthesis and Electrochemical Properties of Mono- and Dimers Derived from Phenylaminoisoquinolinequinones.

Authors:  Juana Andrea Ibacache; Jaime A Valderrama; Judith Faúndes; Alex Danimann; Francisco J Recio; César A Zúñiga
Journal:  Molecules       Date:  2019-11-30       Impact factor: 4.411

9.  High-throughput testing in head and neck squamous cell carcinoma identifies agents with preferential activity in human papillomavirus-positive or negative cell lines.

Authors:  Farhad Ghasemi; Morgan Black; John W Barrett; Paul C Boutros; Anthony C Nichols; Ren X Sun; Frederick Vizeacoumar; Nicole Pinto; Kara M Ruicci; John Yoo; Kevin Fung; Danielle MacNeil; David A Palma; Eric Winquist; Joe S Mymryk; Laurie A Ailles; Alessandro Datti
Journal:  Oncotarget       Date:  2018-05-25
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.